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Enasidenib: a magic bullet for myelodysplastic syndromes?
In The Lancet Haematology, Eytan M Stein and 
colleagues1 present a subgroup analysis of a published 
multicentre phase 1–2 trial (AG221-C-001) of the oral 
drug enasidenib in relapsed or refractory acute myeloid 
leukaemia and myelodysplastic syndromes that harbour 
mutations in the isocitrate dehydrogenase-2 (IDH2) 
gene.2 In their subgroup analysis, the outcomes of 
the few myelodysplastic syndrome cases included in 
AG221-C-001 were extracted from the bulk of the data 
and described in detail. 17 patients with advanced 
myelodysplastic syndromes who were in relapse or 
refractory to previous treatments received enasidenib, 
a specific inhibitor of mutant IDH2, as salvage 
therapy. The paucity of cases examined was a result 
of the low incidence of mutations affecting IDH2 in 
myelodysplastic syndromes (detected in around 5% of 
cases).3 Nevertheless, the presentation of the results in 
myelodysplastic syndromes separated from those in 
acute myeloid leukaemia, despite the limited number of 
observations, is important and might indeed modify the 
standard of care.
Enasidenib was approved in 2017 by the US Food and 
Drug Administration for the treatment of relapsed or 
refractory, IDH2-mutated acute myeloid leukaemia. 
Myelodysplastic syndromes are often considered to be 
in continuum with acute myeloid leukaemias, but in 
fact are molecularly and pathogenetically different.4 
Epigenetic dysregulation and abnormalities in these 
two diseases are not identical4 and, although the two 
conditions share several somatic gene mutations, 
the outcomes of the same therapies are not always 
equal, as a result of the different biology and clinical 
presentations. This variance in outcomes is why the 
results of Stein and co-workers deserve particular 
attention while we await the results of ongoing clinical 
studies of enasidenib (NCT03744390, NCT03383575, 
and NCT03839771) in myelodysplastic syndromes, 
including final results of the AG221-C-001 trial 
(NCT01915498).
The rare IDH2 mutations affect methylation processes 
and epigenetic regulation, determine production of 
the oncometabolite R-2-hydroxyglutarate, and confer 
poor prognosis in myelodysplastic syndromes.5 Few 
treatment options are available for patients with 
myelodysplastic syndromes in whom therapy (mainly 
with hypomethylating drugs) has failed, and survival 
after treatment failure is extremely short, both for 
low-risk and high-risk cases.6 The treating physician is 
left with difficult decisions in the absence of effective 
drugs. Therefore, the number of overall responses 
observed by Stein and colleagues, in more than a half 
of patients (n=9 [53%]) is extremely relevant. The 
patients described received several lines of therapy, 
including haematopoietic stem cell transplant, and 
represented a group with particularly dismal prognosis.6 
Although the small number of cases prompts caution 
in the final judgment of these preliminary results, 
the improvement in overall survival, from around 
5 months usually reported in the literature for relapsed 
or refractory myelodysplastic syndrome cases,6 to a 
median of 16·9 months (95% CI 1·5–32·3) in their study, 
is impressive.
The applicability of target therapy in myelodysplastic 
syndromes depends on the extent of molecular 
characterisation, not only at the onset of disease to 
determine initial prognosis, but also during follow-up, 
and on failure of any line of treatment.7 The identification 
of acquired mutations or their clonal expansion might 
allow new targeted treatment approaches, such as 
with enasidenib.7 Given the increasing availability 
and expansion of molecular testing, haematologists 
should keep molecular characterisation in mind when 
re-evaluating patients to select a rescue therapy.
The authors observed that enasidenib-responsive 
patients carried fewer co-mutations in addition 
to mutation in IDH2. The prognostic weight of the 
number of concurrent mutations on overall survival is 
established in myelodysplastic syndromes;8 however, 
the effect of co-mutations on response to various 
treatments, although suggested for some drugs, is 
controversial and needs to be further clarified.
The clonal architecture of myelodysplastic syndromes 
is modified during the natural history of the disease and 
determines its progression. How these modifications 
influence or correlate with response to therapy is a 
subject that needs further investigation. An improved 
understanding of the relative importance of single 
mutations, their interactions when co-expressed, and 
the importance of allele burden is the aim of future 
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this monotherapy is able to achieve a response, at least 
for a notable period, in the rare cases of myelodys-
plastic syndromes with mutations in IDH2.1 Possible 
combination with other active drugs will provide new 
and promising perspectives in the treatment of this 
small, but prognostically disadvantaged, subgroup of 
patients with myelodysplastic syndromes.
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allele frequency of mutated IDH2 during therapy were 
not reported. If and how variant allele frequency is 
modulated could be a clue to clarifying the mechanism 
of action and efficacy of enasidenib.
In their cohort of patients with advanced myelo-
dysplastic syndromes, Stein and colleagues found that 
enasidenib was not able to eradicate disease, which 
could have been related to the expansion of other clones 
present, limiting the efficacy of monotherapy with 
enasidenib,9 although other mechanisms of resistance 
have also been described.10
For decades, researchers have aimed at finding so-
called magic bullet therapies against haematological 
malignancies. They are now in the position to evaluate 
the positive results of specific, molecularly targeted 
drugs, beginning with all-trans retinoic acid, and 
subsequently progressing to imatinib, ibrutinib, and 
midostaurin, among others. Particularly in acute 
myeloid leukaemia and myelodysplastic syndromes, 
the idea of successfully removing the maturation 
blockage and inducing cell differentiation has been a 
long-standing theme in preclinical and clinical studies. 
With enasidenib, this differentiation has been achieved 
in acute myeloid leukaemia.2 In their study, Stein and 
colleagues showed that rapid differentiation of fast and 
long-lasting effect is also obtainable in IDH2-mutated 
myelodysplastic syndromes, which was reflected in the 
improvement in survival.
Enasidenib combines adequate tolerability, oral 
administration, and high activity into a single therapy. 
Stein and colleagues showed, for the first time, that 
